OxVax Company
OxVax focused on the development of an advanced next-generation dendritic cell vaccine platform for the treatment of solid tumor cancers.
Headquarters:
Oxford, Oxfordshire, United Kingdom
Funding Status:
Seed
Last Funding Type:
Seed
Last Funding Date:
2021-04-21
Investors Number:
2
Founded Date:
2021-01-01
Industry:
Dendritic Cells